Skip to main content
. 2001 Oct;126(1):173–179. doi: 10.1046/j.1365-2249.2001.01654.x

Fig. 2.

Fig. 2

Anti-RPL7 (a) and anti-HUVEC cell surface antibodies (b) were measured by ELISA using stored sequential sera from a patient who developed RPL7 antibodies following transplantation. A significant increase in both anti-RPL7 and anti-HUVEC antibodies is seen at week 17 during which time the patient suffered a rejection episode. At 44 weeks post-transplant levels of anti-HUVEC antibodies have receded to pretransplant levels although anti-RPL7 (IgG) are significantly elevated. This patient was diagnosed with CAD at week 56. The normal O.D. range for anti-RPL7 antibodies in this experiment was IgG 0·175 (s.d. 0·043) IgM 0·166 (s.d. 0·037) and for anti-HUVEC IgG 0·190 (s.d. 0·037) IgM 0·163 (s.d. 0·055). Asterisks indicate a significant increase in O.D. relative to pretransplant levels (P < 0·05 Student's t-test). ▴, IgG; •, IgM. P < 0·05 t-test.